Clinical Trials

  • Principal Investigator:

    Pamela U Freda, MD
    Growth hormone and insulin-like growth-factor 1 (IGF-1) are two hormones that are very important to human growth and metabolism. In disorders of GH and IGF-1 excess and deficiency, significant growth and metabolic abnormalities can develop. This study investigates the effects of GH on the appetite-stimulating hormone AgRP (agouti-related peptide) and the effect of the weight loss medication "Liraglutide" on AgRP. This study is open to healthy subjects and patients with known GH deficiency who are between the ages of 18 and 45. Study participants will be asked to come for a screening visit and...
  • Principal Investigator:

    Robin S. Goland, MD
    A future without Type 1 Diabetes (T1D) starts with you. Get screened! Thanks in large part to T1D family members, we understand T1D as a disease that progresses in three distinct stages. This new definition in conjunction with TrialNet's Pathway to Prevention screening, allows for earlier detection and intervention.
  • Principal Investigator:

    Robin S. Goland, MD
    A future without Type 1 Diabetes (T1D) starts with you. Get screened! Thanks in large part to T1D family members, we understand T1D as a disease that progresses in three distinct stages. This new definition in conjunction with TrialNet's Pathway to Prevention screening, allows for earlier detection and intervention.
  • Principal Investigator:

    Rudolph L. Leibel, MD
    The Physiology of the Weight Reduced State (POWERS) is a national research study designed to discover and learn what happens to the human body after weight loss and to learn why some people regain their lost weight. Understanding why this happens could help health professionals improve strategies for successful weight loss maintenance after weight loss. POWERS is a research study with a goal to understand the changes in the body that occur after weight loss and learn how these changes affect the ability to keep the weight off. It involves universities, medical centers, researchers, and most...
  • Principal Investigator:

    Judy Korner, MD
    The purpose of this study is to evaluate if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The participation lasts ten months and includes six in-person visits at CUIMC with blood sampling and questionnaires, virtual nutritional counseling, and taking an oral weight loss medication for 28 weeks.
Back to top